Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Purpose of this notification is to reinforce important information regarding the safe use of medtronic insulin pumps. medtronic has received a small number of reports regarding users who have unintentionally programmed the pump to deliver the maximum bolus amount including one incident that resulted in severe hypoglycemia. the inadvertent selection and delivery of a bolus amount that exceeds the amount intended by the user can result in hypoglycemia. medtronic is notifying all paradigm pump users health care professionals and certified pump trainers of the function of the wrap around scrolling feature and make them aware of the potential for user error.
Model Catalog: MMT-554 (Lot serial: All lots); Model Catalog: MMT-722 (Lot serial: All lots); Model Catalog: MMT-754 (Lot serial: All lots); Model Catalog: MMT-522 (Lot serial: All lots); Model Catalog: MMT-515 (Lot serial: All lots); Model Catalog: MMT-712 (Lot serial: All lots); Model Catalog: MMT-715 (Lot serial: All lots); Model Catalog: MMT-512 (Lot serial: All lots); Model Catalog: MMT-511 (Lot serial: All lots)
“If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.